APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live Attenuated Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Live Attenuated Vaccines Market Outlook and Growth Opportunities 2026

20 December 2025198 pages

Choose your research edition.

Industry ResearchLive Attenuated Vaccines Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Live Attenuated Vaccines Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Live Attenuated Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live Attenuated Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Live Attenuated Vaccines Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Live Attenuated Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Live Attenuated Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Live Attenuated Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Live Attenuated Vaccines market include Astellas Pharma, CSL, Serum Institute Of India, GlaxoSmithKline, Pfizer, Merck, Johnson & Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Live Attenuated Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Live Attenuated Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Live Attenuated Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Live Attenuated Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Live Attenuated Vaccines Segment by Company

Astellas Pharma

CSL

Serum Institute Of India

GlaxoSmithKline

Pfizer

Merck

Johnson & Johnson

Sanofi

Live Attenuated Vaccines Segment by Type

Bacterial

Viral

Live Attenuated Vaccines Segment by Application

Research Institutes

Hospitals

Clinics

Others

Live Attenuated Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Live Attenuated Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Live Attenuated Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Live Attenuated Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Live Attenuated Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live Attenuated Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live Attenuated Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live Attenuated Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Live Attenuated Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Live Attenuated Vaccines industry.

Chapter 3: Detailed analysis of Live Attenuated Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Live Attenuated Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Live Attenuated Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Live Attenuated Vaccines Industry Trends Table 2. Live Attenuated Vaccines Industry Drivers Table 3. Live Attenuated Vaccines Industry Opportunities and Challenges Table 4. Live Attenuated Vaccines Industry Restraints Table 5. Global Live Attenuated Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Live Attenuated Vaccines Revenue Share by Company (2021-2026) Table 7. Global Live Attenuated Vaccines Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Live Attenuated Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Live Attenuated Vaccines Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Live Attenuated Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Live Attenuated Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Live Attenuated Vaccines Company, Product Type & Application Table 13. Global Live Attenuated Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Live Attenuated Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Bacterial Table 18. Significant Companies of Viral Table 19. Global Live Attenuated Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Live Attenuated Vaccines Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Live Attenuated Vaccines Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Live Attenuated Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Live Attenuated Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Live Attenuated Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Live Attenuated Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Live Attenuated Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Live Attenuated Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Live Attenuated Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Research Institutes Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Clinics Table 32. Significant Companies of Others Table 33. Global Live Attenuated Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Live Attenuated Vaccines Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Live Attenuated Vaccines Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Live Attenuated Vaccines Sales Volume Share by Application (2021-2026) Table 37. Global Live Attenuated Vaccines Sales Volume Share by Application (2027-2032) Table 38. Global Live Attenuated Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Live Attenuated Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Live Attenuated Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Live Attenuated Vaccines Sales Value Share by Application (2021-2026) Table 42. Global Live Attenuated Vaccines Sales Value Share by Application (2027-2032) Table 43. Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Live Attenuated Vaccines Sales by Region (2021-2026) & (K Units) Table 45. Global Live Attenuated Vaccines Sales Market Share by Region (2021-2026) Table 46. Global Live Attenuated Vaccines Sales by Region (2027-2032) & (K Units) Table 47. Global Live Attenuated Vaccines Sales Market Share by Region (2027-2032) Table 48. Global Live Attenuated Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Live Attenuated Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Live Attenuated Vaccines Sales Value Share by Region (2021-2026) Table 51. Global Live Attenuated Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Live Attenuated Vaccines Sales Value Share by Region (2027-2032) Table 53. Global Live Attenuated Vaccines Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Live Attenuated Vaccines Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Live Attenuated Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Live Attenuated Vaccines Sales by Country (2021-2026) & (K Units) Table 58. Global Live Attenuated Vaccines Sales Market Share by Country (2021-2026) Table 59. Global Live Attenuated Vaccines Sales by Country (2027-2032) & (K Units) Table 60. Global Live Attenuated Vaccines Sales Market Share by Country (2027-2032) Table 61. Global Live Attenuated Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Live Attenuated Vaccines Sales Value Market Share by Country (2021-2026) Table 63. Global Live Attenuated Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Live Attenuated Vaccines Sales Value Market Share by Country (2027-2032) Table 65. Astellas Pharma Company Information Table 66. Astellas Pharma Business Overview Table 67. Astellas Pharma Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Astellas Pharma Live Attenuated Vaccines Product Portfolio Table 69. Astellas Pharma Recent Development Table 70. CSL Company Information Table 71. CSL Business Overview Table 72. CSL Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. CSL Live Attenuated Vaccines Product Portfolio Table 74. CSL Recent Development Table 75. Serum Institute Of India Company Information Table 76. Serum Institute Of India Business Overview Table 77. Serum Institute Of India Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Serum Institute Of India Live Attenuated Vaccines Product Portfolio Table 79. Serum Institute Of India Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. GlaxoSmithKline Live Attenuated Vaccines Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Live Attenuated Vaccines Product Portfolio Table 89. Pfizer Recent Development Table 90. Merck Company Information Table 91. Merck Business Overview Table 92. Merck Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Merck Live Attenuated Vaccines Product Portfolio Table 94. Merck Recent Development Table 95. Johnson & Johnson Company Information Table 96. Johnson & Johnson Business Overview Table 97. Johnson & Johnson Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Johnson & Johnson Live Attenuated Vaccines Product Portfolio Table 99. Johnson & Johnson Recent Development Table 100. Sanofi Company Information Table 101. Sanofi Business Overview Table 102. Sanofi Live Attenuated Vaccines Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Sanofi Live Attenuated Vaccines Product Portfolio Table 104. Sanofi Recent Development Table 105. Key Raw Materials Table 106. Raw Materials Key Suppliers Table 107. Live Attenuated Vaccines Distributors List Table 108. Live Attenuated Vaccines Customers List Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Live Attenuated Vaccines Product Image Figure 2. Global Live Attenuated Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live Attenuated Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Live Attenuated Vaccines Sales (2021-2032) & (K Units) Figure 5. Global Live Attenuated Vaccines Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Live Attenuated Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Bacterial Image Figure 10. Viral Image Figure 11. Global Live Attenuated Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Live Attenuated Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Live Attenuated Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Live Attenuated Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Live Attenuated Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Live Attenuated Vaccines Sales Value Share by Type (2021-2032) Figure 17. Research Institutes Image Figure 18. Hospitals Image Figure 19. Clinics Image Figure 20. Others Image Figure 21. Global Live Attenuated Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Live Attenuated Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Live Attenuated Vaccines Sales Volume Share by Application (2021-2032) Figure 24. Global Live Attenuated Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Live Attenuated Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Live Attenuated Vaccines Sales Value Share by Application (2021-2032) Figure 27. Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Live Attenuated Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Live Attenuated Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Live Attenuated Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Live Attenuated Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. North America Live Attenuated Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Live Attenuated Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Live Attenuated Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Live Attenuated Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Live Attenuated Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Live Attenuated Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. South America Live Attenuated Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Live Attenuated Vaccines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Live Attenuated Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Live Attenuated Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Live Attenuated Vaccines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Live Attenuated Vaccines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial
  • Viral
Applications
  • Research Institutes
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Astellas Pharma
  • CSL
  • Serum Institute Of India
  • GlaxoSmithKline
  • Pfizer
  • Merck
  • Johnson & Johnson
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Live Attenuated Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Live Attenuated Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Live Attenuated Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Live Attenuated Vaccines Market Dynamics
  1. 2.1 Live Attenuated Vaccines Industry Trends
  2. 2.2 Live Attenuated Vaccines Industry Drivers
  3. 2.3 Live Attenuated Vaccines Industry Opportunities and Challenges
  4. 2.4 Live Attenuated Vaccines Industry Restraints
3 Live Attenuated Vaccines Market by Company
  1. 3.1 Global Live Attenuated Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Live Attenuated Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Live Attenuated Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Live Attenuated Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Live Attenuated Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Live Attenuated Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Live Attenuated Vaccines Company Product Type and Application
  8. 3.8 Global Live Attenuated Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Live Attenuated Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Live Attenuated Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Live Attenuated Vaccines Market by Type
  1. 4.1 Live Attenuated Vaccines Type Introduction
  2. 4.1.1 Bacterial
  3. 4.1.2 Viral
  4. 4.2 Global Live Attenuated Vaccines Sales Volume by Type
  5. 4.2.1 Global Live Attenuated Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Live Attenuated Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Live Attenuated Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Live Attenuated Vaccines Sales Value by Type
  9. 4.3.1 Global Live Attenuated Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Live Attenuated Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Live Attenuated Vaccines Sales Value Share by Type (2021-2032)
5 Live Attenuated Vaccines Market by Application
  1. 5.1 Live Attenuated Vaccines Application Introduction
  2. 5.1.1 Research Institutes
  3. 5.1.2 Hospitals
  4. 5.1.3 Clinics
  5. 5.1.4 Others
  6. 5.2 Global Live Attenuated Vaccines Sales Volume by Application
  7. 5.2.1 Global Live Attenuated Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Live Attenuated Vaccines Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Live Attenuated Vaccines Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Live Attenuated Vaccines Sales Value by Application
  11. 5.3.1 Global Live Attenuated Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Live Attenuated Vaccines Sales Value by Application (2021-2032)
  13. 5.3.3 Global Live Attenuated Vaccines Sales Value Share by Application (2021-2032)
6 Live Attenuated Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Live Attenuated Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Live Attenuated Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Live Attenuated Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Live Attenuated Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Live Attenuated Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Live Attenuated Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Live Attenuated Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Live Attenuated Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Live Attenuated Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Live Attenuated Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Live Attenuated Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Live Attenuated Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Live Attenuated Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Live Attenuated Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Live Attenuated Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Live Attenuated Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Live Attenuated Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Live Attenuated Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Live Attenuated Vaccines Sales Value Share by Country, 2025 VS 2032
7 Live Attenuated Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Live Attenuated Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Live Attenuated Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Live Attenuated Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Live Attenuated Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Live Attenuated Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Live Attenuated Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Live Attenuated Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Live Attenuated Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Live Attenuated Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Live Attenuated Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Live Attenuated Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Astellas Pharma
  2. 8.1.1 Astellas Pharma Company Information
  3. 8.1.2 Astellas Pharma Business Overview
  4. 8.1.3 Astellas Pharma Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Astellas Pharma Live Attenuated Vaccines Product Portfolio
  6. 8.1.5 Astellas Pharma Recent Developments
  7. 8.2 CSL
  8. 8.2.1 CSL Company Information
  9. 8.2.2 CSL Business Overview
  10. 8.2.3 CSL Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 CSL Live Attenuated Vaccines Product Portfolio
  12. 8.2.5 CSL Recent Developments
  13. 8.3 Serum Institute Of India
  14. 8.3.1 Serum Institute Of India Company Information
  15. 8.3.2 Serum Institute Of India Business Overview
  16. 8.3.3 Serum Institute Of India Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute Of India Live Attenuated Vaccines Product Portfolio
  18. 8.3.5 Serum Institute Of India Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Live Attenuated Vaccines Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Live Attenuated Vaccines Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck Live Attenuated Vaccines Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Johnson & Johnson
  38. 8.7.1 Johnson & Johnson Company Information
  39. 8.7.2 Johnson & Johnson Business Overview
  40. 8.7.3 Johnson & Johnson Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Johnson & Johnson Live Attenuated Vaccines Product Portfolio
  42. 8.7.5 Johnson & Johnson Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Live Attenuated Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Live Attenuated Vaccines Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Live Attenuated Vaccines Value Chain Analysis
  2. 9.1.1 Live Attenuated Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Live Attenuated Vaccines Sales Mode & Process
  6. 9.2 Live Attenuated Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Live Attenuated Vaccines Distributors
  9. 9.2.3 Live Attenuated Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst